Mapping cancer DNA to match patients with targeted drugs

NCT ID NCT02155621

Recruiting now Knowledge-focused Sponsor: British Columbia Cancer Agency Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study aims to understand advanced cancers by analyzing their complete genetic code. Researchers will take biopsies and blood samples from 5,000 participants to identify genetic 'drivers' of their cancer. The goal is to see if this information helps doctors choose more personalized treatments and to build a large database linking cancer genetics to treatment outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genome sequencing
What this could lead to: If successful, this could help doctors choose more effective, personalized treatments for advanced cancers based on each patient's unique tumor genetics.
What could go wrong: This is an early-stage observational study, not a treatment trial. It may not directly benefit participants, and genomic insights may not always lead to better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCERS CANCERS THAT CANNOT BE TREATED WITH CURATIVE INTENT METASTATIC CANCERS

Mapping cancer DNA to match patients with targeted drugs

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions